paroxetine has been researched along with escitalopram in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coleman, JA; Gouaux, E; Green, EM | 1 |
| Chatard, A; Harika-Germaneau, G; Hashemian, F; Jaafari, N; Lafay-Chebassier, C; Langbour, N; Millet, B; Patri, S; Pérault-Pochat, MC; Solinas, M | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Amada, N; Futamura, T; Hirose, T; Kakumoto, Y; Kikuchi, T; Maeda, K; Suzuki, M | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Chen, YM; Guan, W; Huang, J; Jiang, B; Li, WY; Shi, TS; Xu, DW | 1 |
2 review(s) available for paroxetine and escitalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
6 other study(ies) available for paroxetine and escitalopram
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
X-ray structures and mechanism of the human serotonin transporter.
Topics: Allosteric Regulation; Allosteric Site; Antidepressive Agents; Citalopram; Crystallography, X-Ray; Dopamine Plasma Membrane Transport Proteins; Drug Design; Extracellular Space; Humans; Immunoglobulin Fab Fragments; Intracellular Space; Ions; Ligands; Models, Molecular; Paroxetine; Protein Binding; Protein Conformation; Protein Stability; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2016 |
Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.
Topics: Brain-Derived Neurotrophic Factor; Escitalopram; Humans; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2023 |
The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Antidepressive Agents; Depression; Escitalopram; Fluoxetine; Humans; Mice; Paraventricular Hypothalamic Nucleus; Paroxetine; Serotonin; Stress, Psychological | 2023 |